Statins beneficial for diabetics
This article was originally published in The Tan Sheet
Statin therapy is safe and cost-effective option for reducing the risk of major vascular events in patients with diabetes and should be considered for almost all diabetics, according to a meta-analysis by the Cholesterol Treatment Trialists' Collaborators. The study, which was published in The Lancet Jan. 12 and included 14 trials with 18,686 diabetics and 17,220 non-diabetics, found statin therapy in diabetics was associated with a 9 percent proportional reduction in all-cause mortality per mmol/L reduction in LDL cholesterol, and was associated with a statistically similar 13 percent reduction in all-cause mortality in those without diabetes...
You may also be interested in...
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.
Trade group also compiled website with information and resources to help members "stay up to date and take any necessary steps to mitigate the risks associated with COVID-19." Its members also got a chance to describe potential supply chain disruptions in survey for USDA.